|
|
 |
I study here www.scinopharm.com.tw The Bethesda, Maryland-based National Cancer Institute (NCI)and academic researchers it sponsors have just launched "superresponder" initiatives to match patients having little-knowngene mutations to drugs already shown to help others with thesame mutations, even if their tumors are for a variety oforgans.
2021-2-2 2:11:01 |
|
|
|
